Please Wait

Applying Filters...

J&J’s Intra‑Cellular buyout, BMS’ oncology gambit, Sanofi’s Blueprint acquisition drive mega deals in H1 2025

Data Compilation
#PharmaFlow

Pipeline Prospector May 2025: Pfizer strikes US$ 6 bn oncology pact; Lilly diversifies pipeline with US$ 2.3 bn in deals

Stock Recap
#PipelineProspector

Eloxatin, Oxaliplatin

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

70 API Suppliers, 24 USDMF, 29 CEP/COS, 7 JDMF, 4 EU WC, 25 KDMF, 8 NDC API, 27 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

115 Drugs in Development

115 Drugs in Development

INTERMEDIATES

8 Intermediate Suppliers

8 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

223 FDF Dossiers, 69 FDA Orange Book, 80 Europe, 5 Canada, 4 Australia, 22 South Africa, 43 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INTRAVENOUS - 100MG/20ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INTRAVENOUS - 200MG/40ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INTRAVENOUS - 50MG/10ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INTRAVENOUS - 100MG/20ML (5MG/ML), INJECTABLE;INTRAVENOUS - 50MG/10ML (5MG/ML)

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 1 Faran Shimi Pharmaceutical, 2 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 1 Capital Farma, 2 DFE Pharma, 14 Kerry, 2 Microlex e.U, 1 Pluviaendo, 1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

18 Fillers, Diluents & Binders, 4 Granulation, 3 Direct Compression, 3 Co-Processed Excipients, 2 Solubilizers, 1 Parenteral

DIGITAL CONTENT

41 News #PharmaBuzz

41 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 59 Regulatory FDF Prices, 7 Annual Reports

MARKET PLACE

8 APIs, 18 FDF Dossiers

PATENTS & EXCLUSIVITIES

1 Health Canada Patents

1 Health Canada Patents

REF. STANDARDS & IMPURITIES

5 EDQM, 7 Others

$ Xls download

Filters

Log in to access your PharmaMiles and download the data

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
28/06/2025	Fresenius Kabi AB Brunna	Sweden	Sangjin Corporation	20121102-197-I-103-05	Oxaliplatin	2012-11-02	Fresenius Kabi Oncology Ltd.	India	D-35, Industrial Area Kalyani, Nadia, West Bengal - 741 235, India
28/06/2025	Heraeus Holding	Germany	Korea Pfizer Pharmaceutical Co., Ltd.	20121108-197-I-84-06(2)	Oxaliplatin	2012-11-26	Heraeus Deutschland GmbH & Co. KG_x000D_	Germany	Heraeusstr. 12-14. 63450 Hanau

Contact us
to update this info

Eloxatin, Oxaliplatin

Eloxatin, Oxaliplatin

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

70 API Suppliers

24 USDMF

29 CEP/COS

7 JDMF

4 EU WC

25 KDMF

8 NDC API

27 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

115 Drugs in Development

INTERMEDIATES

8 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

223 FDF Dossiers

69 FDA Orange Book

80 Europe

5 Canada

4 Australia

22 South Africa

43 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INTRAVENOUS - 100MG/20ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INTRAVENOUS - 200MG/40ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INTRAVENOUS - 50MG/10ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INTRAVENOUS - 100MG/20ML (5MG/ML)

INJECTABLE;INTRAVENOUS - 50MG/10ML (5MG/ML)

RELATED EXCIPIENT COMPANIES

1 SPI Pharma

1 Faran Shimi Pharmaceutical

2 Gangwal Healthcare

1 Nanjing Well Pharmaceutical

1 Capital Farma

2 DFE Pharma

14 Kerry

2 Microlex e.U

1 Pluviaendo

1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

18 Fillers, Diluents & Binders

4 Granulation

3 Direct Compression

3 Co-Processed Excipients

2 Solubilizers

1 Parenteral

DIGITAL CONTENT

41 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions

59 Regulatory FDF Prices

7 Annual Reports

MARKET PLACE

8 APIs

18 FDF Dossiers

PATENTS & EXCLUSIVITIES

1 Health Canada Patents

REF. STANDARDS & IMPURITIES

5 EDQM

7 Others

Filters

INJECTABLE;INTRAVENOUS - 100MG/20ML (5MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INTRAVENOUS - 200MG/40ML (5MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INTRAVENOUS - 50MG/10ML (5MG/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons